For help on how to get the results you want, see our search tips.
2 results
Medicine type
Additional monitoring Remove Additional monitoring filter
Conditional approval Remove Conditional approval filter
Exceptional circumstances Remove Exceptional circumstances filter
Generic Remove Generic filter
Medicine
Orphan designations Remove Orphan designations filter
European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter
Referrals Remove Referrals filter
Categories
Human Remove Human filter
Referral authorisation model
Centrally authorised product(s) Remove Centrally authorised product(s) filter
Centrally and nationally authorised products (mixed) Remove Centrally and nationally authorised products (mixed) filter
Referral type
Article 31 referrals Remove Article 31 referrals filter
Article 20 procedures Remove Article 20 procedures filter
Referral status
Procedure started Remove Procedure started filter
-
List item
Referral: Rubraca (updated)
rucaparib, associated names: Rubraca, Article 20 procedures
Status: Procedure started, Last updated: 06/05/2022 -
List item
Referral: Janus Kinase inhibitors (JAKi)
tofacitinib, abrocitinib, baricitinib, upadacitinib, filgotinib, associated names: Xeljanz, Cibinqo, Olumiant, Rinvoq, Jyseleca, Article 20 procedures
Status: Procedure started, Last updated: 11/02/2022